Tuğba ÇETİNTEPE, CELAL ACAR, Şerife SOLMAZ

NON-HODGKIN LENFOMA TANILI HASTALARIMIZIN RETROSPEKTİF DEĞERLENDİRİLMESİ

Giriş: Çalışmamızda Sağlık Bilimleri Üniversitesi Bozyaka Eğitim ve Araştırma Hastanesi Hematoloji Kliniğinde takip edilen 90 Non- Hodgkin lenfoma tanılı (NHL) hastanın demografik verileri, tedavi yanıtları ile sağkalım analizlerinin yapılması amaçlandı. Gereç ve Yöntem: Non- Hodgkin lenfoma tanısı ile izlenen 90 olgunun verileri geriye dönük olarak değerlen- dirildi. Bulgular: Çalışmaya alınan 90 hastadan 47'i kadın,43'i erkekdi. Ortanca yaş 62 olarak saptandı. Hastaların tanılarına bakıldığında 61 hastanın Diffüz büyük B hücreli lenfoma (DBBHL), 15 hastanın marjinal zon lenfoma, 6 hastanın folikuler lenfoma ve 10 hastanın diğer lenfoma tanısı aldığı görüldü. Hastaların 18 tanesi ölmüş, 72 tanesi ise yaşıyor olarak saptandı. Tüm NHL hastalarında ortalama sağkalım süresi 73 ay olarak bulundu. 5 yıllık toplam sağkalım %75, 5 yıllık hastalıksız sağkalım % 68 olarak saptandı. Sonuç: Hastalarımızın demografik özellikleri diğer çalışmalar ile benzerdir. Ayrıca tedavi yanıtlarımız ve sağkalım oranlarımız literature ile uyumlu bulunmuştur.

RETROSPECTIVE EVALUATION OF OUR PATIENTS WITH DIAGNOSIS NON-HODGKIN LYMPHOMA

Introduction: Demografic features, respond the treatment of 90 Non-Hodgkin lymphoma (NHL) patients observed at depertman of hematology, Bozyaka Traning and Research Hospital in our study. Material and Method: Data of 90 NHL patients were evaluated retrospectively. Results: We found that 47 of the patients were women and 43 of the patients and were men and median age were 62. The patients were diagnosed with diffuse large B-cell lymphoma (DBBHL) in 61 patients, marginal zone lymphoma in 15 patients, follicular lymphoma in 6 patients and other lymphoma in 10 patients 18 patients died, and 72 of them lived. We found the median survival 73 months all of the patients. All patients survival (OS) was 75% and disease free- survival rates 68% of 5 year. Conclusion: Demografic features of patients are similar to another studies. Our treatment response and survival rates were also found to be consistent with the literature.

PDF

___

Kenneth F. Lymphomas. In: Beutler E, Lictman M, Kipps T, Seligsohn U, editors. Williams Hematology, 6th ed. New-York: Mc Graw-Hill Companies; 2001: p.1237-63.
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64(4): 252-71.
Müller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005; 84(1): 1-12.
Couderc B, Dujols JP, Mokhtari F, Norkowski JL, Slawinski JC, Schlaifer D. The management of adult aggressive non- Hodgkin's lymphomas. Crit Rev Oncol Hematol 2000; 35(1): 33-48.
el-Akkad SM, Amer MH, Lin GS, Sabbah RS, Godwin JT. Pattern of cancer in Saudi Arabs referred to King Faisal Specialist Hospital. Cancer 1986; 58(5): 1172-8.
Isikdogan A, Ayyildiz O, Buyukcelik A, Arslan A, Tiftik N, Buyukbayram H,et al. Non-Hodgkin's lymphoma in southeast Turkey: clinicopathologic features of 490 cases. Ann Hematol 2004; 83(5): 265-9.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19): 5019-32
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 134.
Intragumtornchai T, Rotnakkarin P, Sutcharitchan P, Wannagrairoj P.Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4(1): 52-5.
Alıcı S, Bavbek S, Kaytan E, Başaran M, Eralp Y, Onat H. Aggressive non-Hodgkin’s Lymphoma treated at the Institute of Oncology, Istanbul: treatment, outcome, and prognostic factors. Am J Clin Oncol 2002; 25(5): 502-8.
Kılçıksız S, Payzın B, Çağlar BU, Gökçe T, Yersal Ö, Deniz S. Non-Hodgkin lenfomalı olgularda standart prognostik faktörlerin 50 ve 60 yaş üstü-altı için değerlendirilmesi ve pik yaşı. Türk Onkoloji Dergisi 2006; 21(1): 11-9.
.Conconi A, Zucca E, Roggero E, Bertoni F, Bernasconi A, Mingrone W, et al. Prognostic models for diffuse large B-cell lymphoma. Hematol Oncol 2000; 18(2): 61-73.
Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, et al. International Non-Hodgkin’s Lymphoma Prognostic factors Project. A Predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329(14): 987-94.
Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V, et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leukemia & Lymphoma 2002; 43(4): 805-11.
Pamuk GE, Harmandar F, Harmandar O, Turgut B, Tekgündüz E, Demir M, et al. Non-Hodgkin lenfoma vakalarımızın klinik özelliklerinin değerlendirilmesi. Int J Hematol Oncol 2006; 4(16): 185-94.
Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave PM, et al. Hematology: Basic Principles and Practice. Philadelphia: Churchill Livingstone; 2009.
Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I; EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8(9):784-96.
Lee MY, Tan TD, Feng AC, Liu MC. Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution. Am J Hematol 2006; 81(8): 568-75.
Roswall N, Olsen A, Christensen J, Rugbjerg K, Mellemkjaer L. Social inequality and incidence of and survival from Hodgkin lymphoma, nonHodgkinlymphoma and leukaemia in a population-based study in Denmark, 1994-2003. Eur JCancer 2008; 44(14): 2058-73.
Mitterlechner T, Fiegl M, Mühlböck H, Oberaigner W, Dirnhofer S, Tzankov A.Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. J Clin Pathol. 2006; 59(1): 48-55.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(4): 235-42.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109(5): 1857-61.
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7(5): 379-91.
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long Term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). J Clin Oncol 2005; 23(18): 4117-26.